A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse

被引：0
|
作者：
De Groot, J. F. [1 ,2 ,3 ,4 ,5 ]
Prados, M. [1 ,2 ,3 ,4 ,5 ]
Urquhart, T. [1 ,2 ,3 ,4 ,5 ]
Robertson, S. [1 ,2 ,3 ,4 ,5 ]
Yaron, Y. [1 ,2 ,3 ,4 ,5 ]
Sorensen, A. G. [1 ,2 ,3 ,4 ,5 ]
Norton, A. [1 ,2 ,3 ,4 ,5 ]
Batchelor, T. [1 ,2 ,3 ,4 ,5 ]
Drappatz, J. [1 ,2 ,3 ,4 ,5 ]
Wen, P. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Exelixis Inc, San Francisco, CA USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2047
引用
收藏
页数：2
相关论文
共 50 条
  • [31] PHASE I/II STUDY OF ENZASTAURIN (ENZ) PLUS TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (XRT) IN PATIENTS (PTS) WITH GLIOBLASTOMA MULTIFORME (GBM) OR GLIOSARCOMA (GS)
    Butowski, N.
    Lamborn, K.
    Chang, S.
    Page, M.
    Parvataneni, R.
    Chang, S.
    Liepa, A. M.
    Nicol, S.
    Thornton, D.
    Prados, M.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1073 - 1074
  • [32] Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.
    Gordon, M. S.
    Vogelzang, N. J.
    Schoffski, P.
    Daud, A.
    Spira, A. I.
    O'Keeffe, B. A.
    Rafferty, T.
    Lee, Y.
    Berger, R.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC)
    Salgia, R.
    Sherman, S.
    Hong, D. S.
    Ng, C. S.
    Frye, J.
    Janisch, L.
    Ratain, M. J.
    Kurzrock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Phase II study of temozolamide in patients with glioblastoma multiforme
    Janinis, J
    Tsantila, A
    Samantas, E
    Aravantinos, G
    Sitaras, N
    Skarlos, D
    ANNALS OF ONCOLOGY, 1998, 9 : 181 - 181
  • [35] Imatinib plus hydroxyurea: safety and efficacy in pre-treated, progressive glioblastoma multiforme (GBM) patients (pts) - an update on the initial 30 pts
    Dresemann, G.
    EJC SUPPLEMENTS, 2005, 3 (02): : 140 - 140
  • [36] PHASE II STUDY OF IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH A FIRST RECURRENCE OF GLIOBLASTOMA MULTIFORME
    Aoki, T.
    Ueba, T.
    Takahashi, J.
    Miyatake, S.
    Nozaki, K.
    Taki, W.
    Matsutani, M.
    NEURO-ONCOLOGY, 2010, 12 : 48 - 48
  • [37] PHASE II STUDY OF IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH A FIRST RECURRENCE OF GLIOBLASTOMA MULTIFORME
    Aoki, Tomokazu
    Ueba, Tetsuya
    Arakawa, Yoshiki
    Miyatake, Shin-Ichi
    Tsukahara, Tetsuya
    Miyamoto, Susumu
    Nozaki, Kazuhiko
    Taki, Waro
    Matsutani, Masao
    NEURO-ONCOLOGY, 2012, 14 : 67 - 67
  • [38] Phase I study of gefitinib and rapamycin in adult patients with recurrent glioblastoma multiforme (GBM).
    Phuphanich, Surasak
    Chu, Ray
    Yu, John S.
    Black, Keith L.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3462S - 3462S
  • [39] Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure:: A phase II study
    Brandes, AA
    Ermani, M
    Basso, U
    Paris, MK
    Lumachi, F
    Berti, F
    Amistà, P
    Gardiman, M
    Iuzzolino, P
    Turazzi, S
    Monfardini, S
    ONCOLOGY, 2002, 63 (01) : 38 - 41
  • [40] Gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme (GBM): Preliminary results of a phase II study
    Fabi, Alessandra
    Mirri, Alessandra
    Pace, Andrea
    Felici, Alessandra
    Vidiri, Antonello
    Metro, Giulio
    Cognetti, Francesco
    Occhipinti, Emanuele
    Arcangeli, Giorgio
    Carapella, Carmine
    NEURO-ONCOLOGY, 2007, 9 (04) : 530 - 530
12345